Pletal — Competitive Intelligence Brief

Pletal (CILOSTAZOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 3 Inhibitor [EPC]. Area: Metabolic.

marketed Phosphodiesterase 3 Inhibitor [EPC] cGMP-inhibited 3',5'-cyclic phosphodiesterase A Metabolic Small molecule

Target snapshot

Pletal (CILOSTAZOL) — Otsuka.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pletal TARGET	CILOSTAZOL	Otsuka	marketed	Phosphodiesterase 3 Inhibitor [EPC]	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	1999-01-01
Agrylin	ANAGRELIDE	Takeda	marketed	Platelet-reducing Agent	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	1997-01-01
Cartonic	amrinone	Sanofi	marketed	amrinone	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	1984-01-01
Pletal	Pletal	Otsuka America Pharmaceutical	marketed		Cytochrome P450 2C9, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited 3',5'-cyclic phosphodiesterase B
Ohtuvayre	ENSIFENTRINE	Verona Pharma	marketed	Phosphodiesterase 3 Inhibitor [EPC]		2024-01-01
Primacor	Milrinone Lactate	Sanofi	marketed	Phosphodiesterase 3 Inhibitor	Phosphodiesterase 3	1987-01-01
Primacor	MILRINONE	Sanofi	marketed	Phosphodiesterase 3 Inhibitor	Phosphodiesterase 3	1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 3 Inhibitor [EPC] class)

1. Otsuka · 1 drug in this class
2. Verona Pharma · 1 drug in this class